Pulse Biosciences (PLSE) Income from Continuing Operations (2015 - 2025)
Pulse Biosciences' (PLSE) quarterly Income from Continuing Operations came in at 29961000.0 in Q3 2025, down 136.29% year-on-year from 82570197.78 in Q3 2024, and down 56.31% quarter-over-quarter from 19168000.0 in Q2 2025.
Pulse Biosciences (PLSE) Income from Continuing Operations (2015 - 2025) Analysis & Trends
Pulse Biosciences' Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 29961000.0 for Q3 2025.
- On a quarterly basis, Income from Continuing Operations fell 136.29% year-over-year to 29961000.0 in Q3 2025; TTM through Sep 2025 was 21876000.0, a 147.42% increase from a year earlier, with the FY2025 full-year figure at 72800000.0, up 35.82% from the prior year.
- Income from Continuing Operations retreated to 29961000.0 in Q3 2025 per PLSE's latest filing, from 19168000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 87800000.0 in Q4 2024 and bottomed at 29961000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 13996000.0 (2022), against an average of 9701052.63.
- Across the five-year window, Income from Continuing Operations jumped 835.77% in 2024 and slumped 136.29% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 15463000.0 in 2021, then soared by 40.52% to 9197000.0 in 2022, then retreated by 29.75% to 11933000.0 in 2023, then soared by 835.77% to 87800000.0 in 2024, then tumbled by 134.12% to 29961000.0 in 2025.
- Per Business Quant, the three latest PLSE Income from Continuing Operations figures stand at 29961000.0 (Q3 2025), 19168000.0 (Q2 2025), and 16795000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 240.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -37.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 13.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Pulse Biosciences | 2.09 Bn | 2.01 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -29.96 Mn |
| Jun 30, 2025 | -19.17 Mn |
| Mar 31, 2025 | -16.80 Mn |
| Dec 31, 2024 | 87.80 Mn |
| Sep 30, 2024 | -12.68 Mn |
| Jun 30, 2024 | -11.38 Mn |
| Mar 31, 2024 | -10.14 Mn |
| Dec 31, 2023 | -11.93 Mn |
| Sep 30, 2023 | -10.57 Mn |
| Jun 30, 2023 | -9.91 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -9.20 Mn |
| Sep 30, 2022 | -18.04 Mn |
| Jun 30, 2022 | -14.00 Mn |
| Mar 31, 2022 | -17.27 Mn |
| Dec 31, 2021 | -15.46 Mn |
| Sep 30, 2021 | -14.94 Mn |
| Jun 30, 2021 | -20.31 Mn |
| Mar 31, 2021 | -20.57 Mn |
| Dec 31, 2020 | -14.80 Mn |